LA LABResearch Reference Document
Compound Guide
Oxytocin — Neuropeptide Hormone
Quick Start
FDA Approved — Hospital Use Only (IV/IM, Obstetrics)
Oxytocin is FDA-approved as Pitocin for IV/IM administration in hospital obstetric settings — labour induction, postpartum haemorrhage, and uterine atony. Intranasal and subcutaneous administration are investigational (non-approved) routes. This guide covers the investigational research context. Do not confuse research preparations with Pitocin.
What It Is
Oxytocin is a 9-amino acid nonapeptide produced in the hypothalamus (PVN and SON nuclei) and released by the posterior pituitary. It mediates uterine contractions, lactation, and — as a neurotransmitter acting in limbic brain circuits — trust, social bonding, anxiety reduction, and aspects of social cognition. Often called "the bonding hormone."
Research Dosing (Intranasal)
Intranasal: 10–72 IU per session, divided into 2–4 sprays per nostril. The SOARS-B autism trial used up to 48 IU/day. Half-life intranasally: ~20 minutes for direct nasal effects, but downstream brain effects last hours. Note: 1 IU ≈ 2 mcg oxytocin. SubQ dosing (100–500 mcg) does not meaningfully cross the blood-brain barrier — central effects are primarily via intranasal delivery.
Regulatory Status
FDA-approved IV/IM (Pitocin) for obstetric use only — hospital-administered. Intranasal/SubQ are investigational. Not on WADA prohibited list. Research preparations (not Pitocin) used in investigational contexts. For research purposes only.
Dosing Protocols by Route
| Route | Dose | Timing | BBB Penetration | Context |
|---|---|---|---|---|
| Intranasal | 10–72 IU/session | 20–40 min before activity or test | Direct nasal-brain pathway | Central effects (social, cognitive) — primary research route |
| SubQ injection | 100–500 mcg | 20–30 min before | Minimal | Peripheral effects; limited central brain activity |
| IV/IM (Pitocin) | As per obstetric label | Hospital only | Not applicable | Approved use only; not for research settings outside hospitals |
IU to mcg Conversion
1 International Unit (IU) of oxytocin ≈ 2 mcg. Our 2 mg research vial ≈ 1,000 IU. With 3.0 mL BAC water, concentration ≈ 333 IU/mL (≈0.67 mg/mL). For intranasal nasal spray, concentration of the spray solution and spray volume per actuation determine IU per spray — this varies by preparation.
Supplies & Reconstitution
Reconstitution & Dosing
LA LAB supplies Oxytocin as a 2 mg research vial. Reconstitute with 3.0 mL bacteriostatic water for a concentration of ≈0.67 mg/mL (≈333 IU/mL). At a 250 mcg SubQ research dose, draw ≈0.38 mL — about 38 units on a 100-unit insulin syringe. See the dosing table above for route-specific research ranges. Figures are for research reference only.
Reconstitution Steps
01
Warm the vial
Allow vial to reach room temperature from freezer before reconstitution.
02
Swab and draw
Alcohol swab both vial tops, air-dry. Draw required BAC water volume.
03
Inject along the wall
Let BAC water run slowly down the inside glass wall. Do not jet onto the powder.
04
Swirl gently
Swirl until clear. Oxytocin solution should be colourless. Do not shake.
05
Refrigerate
Store at 2–8°C for up to 30 days. Oxytocin is relatively stable in solution under refrigeration. Protect from light. Do not freeze after reconstitution.
Mechanism of Action
Oxytocin Receptor (OXTR)
Binds OXTR (a G-protein coupled receptor) throughout the brain (amygdala, nucleus accumbens, VTA, PFC) and periphery (uterus, breast, heart). Central OXTR activation mediates social bonding, trust, and anxiety modulation.
Amygdala Dampening
Reduces amygdala reactivity to threat and social stressors, studied in fMRI research. This is the proposed mechanism for reduced social anxiety and increased trust observed in controlled laboratory studies (Kirsch et al. 2005 meta-analysis).
Uterine Contraction (Peripheral)
The approved (Pitocin) mechanism: peripheral OXTR on smooth muscle drives uterine contractions for labour induction and haemorrhage control. This peripheral effect is relevant to safety — exogenous oxytocin in pregnancy can cause uterine hyperstimulation.
Short Plasma Half-life
IV half-life: 3–6 minutes. Intranasal effects persist 20 min to hours — the intranasal route produces direct olfactory-to-brain delivery, not through systemic circulation. This is why intranasal and IV oxytocin have very different effects profiles.
Key Human Research
| Study | Design | Key Finding |
|---|---|---|
| Kirsch et al. 2005 | RCT; intranasal; trust game paradigm | Intranasal oxytocin increased trust in a financial game vs placebo — landmark study |
| SOARS-B (NEJM 2021) | RCT; n=290; autism spectrum disorder; 24 weeks; up to 48 IU/day intranasal | NO significant difference in social responsiveness scale vs placebo — negative primary endpoint |
| Social anxiety studies | Multiple; intranasal; healthy volunteers | Reduced amygdala reactivity to threatening faces on fMRI; anxiety reduction not consistent across studies |
| Attachment theory research | Observational; intranasal studies | Enhanced mother-infant synchrony observed; effects context-dependent and not always replicable |
Replication Crisis in Oxytocin Research
The oxytocin research field has faced significant replication challenges. Many early findings (e.g. trust, generosity, eye contact effects) have not replicated in larger, pre-registered studies. Meta-analyses show highly heterogeneous effects across populations, doses, and contexts. The SOARS-B trial's negative result in autism is a key example. Interpret positive findings with caution.
Storage
| State | Temperature | Duration | Notes |
|---|---|---|---|
| Lyophilised (powder) | −20°C (freezer) | Up to 24 months | Protect from moisture; oxytocin is relatively stable lyophilised |
| Reconstituted (liquid) | 2–8°C (refrigerator) | Up to 30 days | More stable than most peptides once reconstituted; still protect from light |
| Short-term (travel) | <25°C | Up to 72 hours | Avoid heat and direct sunlight |
Disclaimer
This document is an educational research reference only. Oxytocin is FDA-approved only as Pitocin for IV/IM obstetric use in hospitals. Intranasal and SubQ routes are investigational. The research evidence base has significant replication issues. Do not confuse research preparations with Pitocin. By purchasing from LA LAB you confirm you are 18+ and that products are for research purposes only.
Side Effects & What People Report
Oxytocin is a licensed medicine — but by intravenous infusion in obstetrics, under monitoring. The intranasal route people use for mood and social effects is a different thing entirely, studied in small trials with mixed results.
| Reported | Detail |
|---|---|
| Nasal irritation | The intranasal route; stinging or dryness. |
| Headache | Commonly reported. |
| Drowsiness or calm | Often the intended effect; can be unwelcome during the day. |
| Emotional flatness or tearfulness | Reported by some users. Oxytocin is not uniformly “feel-good” — it can amplify whatever the emotional context already is. |
| Water retention / low sodium | The serious one. Oxytocin has antidiuretic activity; at high doses with high fluid intake this can cause dangerous hyponatraemia. |
The dose gap is the thing to understand
Obstetric oxytocin is given intravenously in a hospital with fluid balance monitored, because water retention and low blood sodium are real and dangerous at those doses. Intranasal research doses are far smaller — but the same physiology applies, and drinking heavily while dosing repeatedly is the way people get into trouble.
Who Should Avoid Oxytocin
| Situation | Why |
|---|---|
| Pregnancy | Avoid entirely outside medical supervision. Oxytocin causes uterine contractions — that is its licensed use, in a controlled setting. |
| Heart, kidney or liver disease | Fluid and sodium handling matter here; not studied at these doses. |
| History of hyponatraemia, or on diuretics | The antidiuretic effect is the main risk. |
| Under 18 | No data. |
| Using it to treat a psychiatric condition | Trials in autism, anxiety and PTSD have been small and inconsistent. This is not established treatment. |
Frequently Asked Questions
Does intranasal oxytocin actually reach the brain?
This is genuinely disputed among researchers. Some studies show central effects; others question how much crosses at all. It is the central open question about the whole intranasal approach.
This is genuinely disputed among researchers. Some studies show central effects; others question how much crosses at all. It is the central open question about the whole intranasal approach.
Will it make me feel love or bonding?
The “love hormone” framing oversells it. Trial results are mixed, and oxytocin appears to amplify existing social context rather than create good feelings from nothing.
The “love hormone” framing oversells it. Trial results are mixed, and oxytocin appears to amplify existing social context rather than create good feelings from nothing.
Does it help autism or social anxiety?
Trials have been small and results inconsistent. Several larger, better-designed trials found no benefit. It is not established treatment for either.
Trials have been small and results inconsistent. Several larger, better-designed trials found no benefit. It is not established treatment for either.
How quickly does it work?
Research protocols typically test effects 30–45 minutes after dosing.
Research protocols typically test effects 30–45 minutes after dosing.
Can I use it every day?
Nothing establishes long-term safety by this route, and receptor downregulation with continuous use is a reasonable concern that has not been studied.
Nothing establishes long-term safety by this route, and receptor downregulation with continuous use is a reasonable concern that has not been studied.
Does it help with sleep?
Some users report calm and easier sleep. It has not been trialled for that.
Some users report calm and easier sleep. It has not been trialled for that.
Sources & Research
Leng G, Ludwig M. Intranasal Oxytocin: Myths and Delusions. Biol Psychiatry 2016;79:243–50.
MacDonald E et al. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology 2011;36:1114–26.
Sikich L et al. Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder. N Engl J Med 2021;385:1462–1473. — a large trial that found no benefit.
Regulatory status — licensed for obstetric use by injection. The intranasal route for mood or social effects is not approved anywhere.
Educational reference only
This document is a research reference, not medical advice and not a treatment plan. Oxytocin is licensed only for obstetric use by injection; the intranasal route used here is not approved and its trial results are inconsistent. Dose decisions belong to you and your prescriber. Independent certificates of analysis for every LA LAB batch are published under Research → Lab Results, with the Janoshik task number and verification key so you can check them yourself.